Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPBWR1 | P48145 | 8/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.45 |
| ▸ | PDE1A | P54750 | 3/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL540608 | 0.75 | MAPT (0.49) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL2804194 | 0.74 | PDE1A (0.43) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL2804703 | 0.73 | ALDH1A1 (0.49) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL15555724 | 0.73 | LMNA (0.50) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL2804699 | 0.73 | ALDH1A1 (0.48) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL2490215 | 0.72 | ALDH1A1 (0.43) | MAPTALDH1A1LMNASMN1; SMN2HPGD | |
| SCHEMBL25237607 | 0.72 | LMNA (0.52) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL3717372 | 0.72 | LMNA (0.52) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL20176616 | 0.72 | LMNA (0.52) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 | |
| SCHEMBL15555752 | 0.72 | LMNA (0.52) | MAPTALDH1A1LMNASMN1; SMN2NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906928-B2 | Substituted pyrazolo-pyrrolo-pyridine-dione compounds | ARQULE, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906928-B2 | Substituted pyrazolo-pyrrolo-pyridine-dione compounds | ARQULE, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906928-B2 | Substituted pyrazolo-pyrrolo-pyridine-dione compounds | ARQULE, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2414357-A1 | PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ArQule, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010114904-A1 | PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010114904-A1 | PYRAZOLO-PYRROLOPYRIDINE-DIONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249120-A1 | SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249120-A1 | SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100249120-A1 | SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249120-A1 | SUBSTITUTED PYRAZOLO-PYRROLO-PYRIDINE-DIONE COMPOUNDS | MKI67, TP53, PDK1 | MAPT 2163/4885ALDH1A1 1053/4885LMNA 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.